Keywords
Last Name
Institution

Ariel Berlinski

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPediatrics, College of Medicine
DivisionPeds Pulmonary
Address ACH Administration
1900 Maryland Street
Mail Slot # 512-17
Little Rock AR 72202
Phone501-364-1006
vCardDownload vCard

    Collapse Research Funds 
    Collapse principal investigator
    Funding Agency: Cystic Fibrosis Foundation - Title: 17-18 Cystic Fibrosis Registry Database - Start Date: 2017-07-01

    Funding Agency: Anthera Pharmaceuticals, Inc. - Title: A Phase 3, Randomized, Open-Label Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency - Start Date: 2017-06-01

    Pass Through Agency: Rho World - Funding Agency: Anthera Pharmaceuticals, Inc. - Title: A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency - Start Date: 2016-08-01

    Funding Agency: Cystic Fibrosis Foundation - Title: 16-17 Cystic Fibrosis Registry - Start Date: 2016-07-01

    Funding Agency: Vertex Pharmaceuticals Incorporated - Title: A Phase 2a, Randomized, Double-Blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX371 in subjects aged 12 year or older with CF - Start Date: 2016-03-21

    Funding Agency: Vertex Pharmaceuticals Incorporated - Title: A Phase 3, Open-Label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with CF - Start Date: 2015-10-01

    Funding Agency: Novartis Pharmaceuticals Corporation - Title: A Phase IV prospective observational study in cystic fibrosis patients with chronic respiratory Pseudomonas aeruginosa infection treated with TOBI Podhaler or other FDA approved inhaled antipseudomonal antibacterial drugs - Start Date: 2015-05-01

    Funding Agency: Vertex Pharmaceuticals Incorporated - Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination with Ivacaftor in Subjects aged 12 Years and Older with Cystic Fibrosis, Homozygous for the F508del-DFTR Mutation - Start Date: 2015-03-16

    Funding Agency: Cystic Fibrosis Foundation - Title: 15 16 Cystic Fibrosis Foundation Registry Data Grant - Start Date: 2014-07-01

    Pass Through Agency: Seattle Children's Hospital - Funding Agency: National Heart Lung and Blood Institute - Title: Optimizing Treatment for Early Pseudomonas aeruginosa Infection in CF: OPTIMIZE - Start Date: 2014-04-01

    Pass Through Agency: PPD Development, LP - Funding Agency: MicroDose Therapeutx, Corp. - Title: An Open-Label, Non-drug Proof-of-Concept Study to Assess the Performance of the Fireback Tidal Inhaler in Infants and Children with Acute Respiratory Syncytial Virus Infection - Start Date: 2013-12-01

    Funding Agency: Registrat, Inc. - Title: Point Prevalence Study of Antibodies to Selected Porcine Viruses - Start Date: 2013-10-17

    Funding Agency: Vertex Pharmaceuticals Incorporated - Title: A Phase 3, Rollover study to evaluate the safety and efficacy of long-term treatment with Lumacaftor in combination with Ivacaftor in subjects aged 12 years and older with CF - Start Date: 2013-10-01

    Funding Agency: Cystic Fibrosis Foundation - Title: 13-14 Cystic Fibrosis Foundation Registry Data Grant - Start Date: 2013-07-01

    Funding Agency: Quintiles, Inc. - Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combo with Ivacaftor in subjects aged 12 years adn older with CF - Start Date: 2013-06-03

    Funding Agency: Genentech, Inc. - Title: A Phase IV Multicenter, Randomized, Open Label, Two-Period Crossover Study in Patients with Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by The Erapid Nebulizer System - Start Date: 2012-11-27

    Funding Agency: Philips Respironics - Title: Drug Delivery via Pressurized Metered-Dose Inhaler and Valve Holding Chamber in Asthmatic Children: determination of Delivered Dose Following Coordinated and Uncoordinated Use - Start Date: 2012-09-01

    Pass Through Agency: Seattle Children's Hospital - Funding Agency: CFF - Title: A Long-Term Prospective Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors - Start Date: 2012-06-01

    Funding Agency: CFF - Title: CF Therapeutics Development Center - Start Date: 2012-01-01


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Berlinski A, Pennington D. Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics. Respir Care. 2017 Sep; 62(9):1123-1130. PMID: 28611228.
      View in: PubMed
    2. Perry TT, Marshall A, Berlinski A, Rettiganti M, Brown RH, Randle SM, Luo C, Bian J. Smartphone-based vs paper-based asthma action plans for adolescents. Ann Allergy Asthma Immunol. 2017 Mar; 118(3):298-303. PMID: 28111110.
      View in: PubMed
    3. Berlinski A, Ari A, Davies P, Fink J, Majaesic C, Reychler G, Tatla T, Amirav I. Workshop Report: Aerosol Delivery to Spontaneously Breathing Tracheostomized Patients. J Aerosol Med Pulm Drug Deliv. 2017 Aug; 30(4):207-222. PMID: 28075193.
      View in: PubMed
    4. Berlinski A, von Hollen D, Hatley RHM, Hardaker LEA, Nikander K. Drug Delivery in Asthmatic Children Following Coordinated and Uncoordinated Inhalation Maneuvers: A Randomized Crossover Trial. J Aerosol Med Pulm Drug Deliv. 2017 Jun; 30(3):182-189. PMID: 27977309.
      View in: PubMed
    5. Berlinski A, Cooper B. Oronasal and Tracheostomy Delivery of Soft Mist and Pressurized Metered-Dose Inhalers With Valved Holding Chamber. Respir Care. 2016 Jul; 61(7):913-9. PMID: 27006348.
      View in: PubMed
    6. Berlinski A. Transnasal Aerosol Delivery to Pediatric Patients: Jet Versus Vibrating Mesh--Reply. Respir Care. 2015 Oct; 60(10):e168-9. PMID: 26405191.
      View in: PubMed
    7. Cooper B, Berlinski A. Albuterol Delivery via Facial and Tracheostomy Route in a Model of a Spontaneously Breathing Child. Respir Care. 2015 Dec; 60(12):1749-58. PMID: 26286736.
      View in: PubMed
    8. Willis LD, Berlinski A. Mechanical Insufflation-Exsufflation: The Good, the Bad, and the Ugly. Respir Care. 2015 Jul; 60(7):1081-2. PMID: 26113568.
      View in: PubMed
    9. Berlinski A. Assessing New Technologies in Aerosol Medicine: Strengths and Limitations. Respir Care. 2015 Jun; 60(6):833-47; discussion 847-9. PMID: 26070578.
      View in: PubMed
    10. Berlinski A, Willis JR. Effect of Tidal Volume and Nebulizer Type and Position on Albuterol Delivery in a Pediatric Model of Mechanical Ventilation. Respir Care. 2015 Oct; 60(10):1424-30. PMID: 25969513.
      View in: PubMed
    11. Agarwal A, Willis D, Tang X, Bauer M, Berlinski A, Com G, Ward WL, Carroll JL. Transition of respiratory technology dependent patients from pediatric to adult pulmonology care. Pediatr Pulmonol. 2015 Dec; 50(12):1294-300. PMID: 25652000.
      View in: PubMed
    12. El Taoum KK, Xi J, Kim J, Berlinski A. In Vitro Evaluation of Aerosols Delivered via the Nasal Route. Respir Care. 2015 Jul; 60(7):1015-25. PMID: 25587167.
      View in: PubMed
    13. Berlinski A. Effect of mask dead space and occlusion of mask holes on delivery of nebulized albuterol. Respir Care. 2014 Aug; 59(8):1228-32. PMID: 24327744.
      View in: PubMed
    14. Berlinski A. The order of the factors affects a product! Respir Care. 2014 Mar; 59(3):441-2. PMID: 24587481.
      View in: PubMed
    15. Com G, Carroll JL, Castro MM, Tang X, Jambhekar S, Berlinski A. Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis. J Pediatr. 2014 Apr; 164(4):832-8. PMID: 24418473.
      View in: PubMed
    16. Awad S, Williams DK, Berlinski A. Longitudinal evaluation of compressor/nebulizer performance. Respir Care. 2014 Jul; 59(7):1053-61. PMID: 24149670.
      View in: PubMed
    17. Berlinski A. In vitro evaluation of positive expiratory pressure devices attached to nebulizers. Respir Care. 2014 Feb; 59(2):216-22. PMID: 23920213.
      View in: PubMed
    18. Xi J, Si X, Zhou Y, Kim J, Berlinski A. Growth of nasal and laryngeal airways in children: implications in breathing and inhaled aerosol dynamics. Respir Care. 2014 Feb; 59(2):263-73. PMID: 23821760.
      View in: PubMed
    19. Berlinski A, Willis JR. Albuterol delivery by 4 different nebulizers placed in 4 different positions in a pediatric ventilator in vitro model. Respir Care. 2013 Jul; 58(7):1124-33. PMID: 23107173.
      View in: PubMed
    20. Kim J, Xi J, Si X, Berlinski A, Su WC. Hood nebulization: effects of head direction and breathing mode on particle inhalability and deposition in a 7-month-old infant model. J Aerosol Med Pulm Drug Deliv. 2014 Jun; 27(3):209-18. PMID: 23808762.
      View in: PubMed
    21. Berlinski A. In-vitro nebulized albuterol delivery in a model of spontaneously breathing children with tracheostomy. Respir Care. 2013; [Epub ahead of print].
    22. Berlinski A. Nebulized albuterol delivery in a model of spontaneously breathing children with tracheostomy. Respir Care. 2013 Dec; 58(12):2076-86. PMID: 23674810.
      View in: PubMed
    23. Robbins K, Lowe G, Berlinski A. Determining Supplemental Oxygen requirements for activities of daily living in an adolescent patient. Respir Care 57(10):1746. 2013.
    24. Awad S, Berlinski A. Longitudinal evaluation of compressor-nebulizer performance during intense utilization. 2013; 187:A4112 .
    25. A Berlinski, S Holt, T Thurman, M Heulitt. Albuterol delivery during mechanical ventilation in an ex-vivo porcine model. International Society for Aerosols in Medicine. 2013.
    26. Kim J, Xi J, Si X, Berlinski A, Su W. . Hood nebulization: effects of head direction and breathing mode on particle inhalability and deposition in a 7 month old infant model. J Aerosol Med Pulm Drug Deliv. 2013.
    27. Berlinski A, Chavez A. Albuterol delivery via metered dose inhaler in a spontaneously breathing pediatric tracheostomy model. Pediatr Pulmonol. 2013 Oct; 48(10):1026-34. PMID: 23129547.
      View in: PubMed
    28. Berlinski A, Willis JR. Aerosol delivery by 4 different nebulizers placed in 4 different positions in a pediatric ventilator in-vitro model. Respir Care. 2012; [Epub ahead of print].
    29. Xi J, Berlinski A, Zhou Y, Greenberg B, Ou X. Breathing resistance and ultrafine particle deposition in nasal-laryngeal airways of a newborn, an infant, a child, and an adult. Ann Biomed Eng. 2012 Dec; 40(12):2579-95. PMID: 22660850.
      View in: PubMed
    30. Berlinski A. An ounce of prevention is worth a pound of cure. Respir Care. 2012 Apr; 57(4):657-8. PMID: 22472505.
      View in: PubMed
    31. Willis LD, Berlinski A. Survey of aerosol delivery techniques to spontaneously breathing tracheostomized children. Respir Care. 2012 Aug; 57(8):1234-41. PMID: 22348743.
      View in: PubMed
    32. A Berlinski, J Hayden. Does Occlusion Of The Mask Holes Improve Nebulized Albuterol Delivery?. AM J Respir Crit Care Med. 2012; 185;2012:A3356.
    33. Myers T, Berlinski A, Rubin B, Dhand R. Aerosol Therapy In Spontaneously Breathing & Mechanically Ventilated Patients: Description, Selection & Issues. Clinical Foundations. 2012; 10:7-11.
    34. A Berlinski. Editorial: An Ounce of Prevention is Worth a Pound of Cure. Respir Care. 2012; 57(4):657-658.
    35. J Xi, JW Kim, Y Zhou, A Berlinski. Growth of nasal-laryngeal airways in children and their implications in breathing and inhaled aerosol dynamics. Respir Care 57(10):1776. 2012.
    36. A Berlinski. Aerosol physiology and pitfalls using current delivery systems. Pediatr Pulmonol. 2012; Suppl 35:146-148.
    37. Willis D, Berlinski A. A Survey of Aerosol Delivery Techniques to Spontaneously Breathing Tracheostomized Children. 2012.
    38. A Berlinski, J Hayden. Does Occlusion Of The Mask Holes Improve Nebulized Albuterol Delivery?. Am. J Respir Crit Care Med 185;A3356. 2012.
    39. D Geller, A Berlinski. Pediatric Pulmonology. Aerosol Delivery of Medication. 2011.
    40. A Berlinski, Com G, Melguizo M, Jambhekar S. Effect of Position and Lenght of Nebulizer's Reservoir on Albuterol Characteristics and Solution Output. Am. J Respir Crit Care Med. 2011.
    41. Xi J, Si X, Kim JW, A Berlinski. Simulation of Airflow and Aerosol Deposition in the Nasal Cavity of a 5-year-old Child. J Aerosol Science. 2011; 42(1):156-173.
    42. A Berlinski, G Lowe, Heulitt M. Wegener's Granulomatosis Seen in an Adolescent Female with Broncho-Pleural Fistula. Respir Care. 2011.
    43. Randy Willis, A Berlinski. Albuterol Delivery by Three Different Nebulizers Placed in Four Different Positions In a Heated Wire Ventilator Circuit Utilizing a Pediatric Ventilator In-Vitro Model. Respir Care. 2011.
    44. A Berlinski, Hayden J. Albuterol Delivery Via Nebulizer in a Spontaneously Breathing Pediatric Tracheostomy Model. J Aerosol Med Pulm Drug Deliv. 2011; 57.
    45. A Berlinski, Hayden J. Effect of Concomitant Use of Positive Expiratory Pressure Devices and Nebulizers on Nebulized Albuterol Characteristics. Ped Pulmonology. 2011.
    46. A Berlinski, J Hayden. Effect of Position and Length of Nebulizer's Reservoir on Albuterol Characteristics and Solution Output. AM J Respir Crit Care Med. 2011.
    47. A Berlinski, A Chavez, S Holt, M Heulitt. Albuterol Delivery Via MDI/Spacer In A Spontaneously Breathing Pediatric Tracheostomy Model: Does Bagging Improve Drug Delivery?. Am. J Respir Crit Care Med. 2011; 183.
    48. Berlinski A, Willis JR, Leisenring T. In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization. Respir Care. 2010 Dec; 55(12):1671-9. PMID: 21122175.
      View in: PubMed
    49. Berlinski A, Willis JR. Albuterol delivery via intrapulmonary percussive ventilator and jet nebulizer in a pediatric ventilator model. Respir Care. 2010 Dec; 55(12):1699-704. PMID: 21122179.
      View in: PubMed
    50. Berlinski A, Hayden JB. Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv. 2010 Dec; 23(6):397-404. PMID: 20958142.
      View in: PubMed
    51. Chavez A, McCracken A, Berlinski A. Effect of face mask dead volume, respiratory rate, and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol. 2010 Mar; 45(3):224-9. PMID: 20146371.
      View in: PubMed
    52. D Willis, A Berlinski. Aerosol Delivery To Spontaneously Breathing Pediatric Patients With A Tracheostomy. American Journal of Respiratory Critical Care Medicine. 2010.
    53. A Chavez, A Berlinski. Factors affecting albuterol deivery via MDI in a spointaneously breathing pediatric trancheostomy model. Am J Respir Crit Care Med. 2010; A3918.
    54. A Berlinski, Willis JR. Albuterol Delivery by Intraulmonary Percussive Ventilator and Jet Nebulizer in a Pediatric Ventilator Model. Respir Care. 2010; 55(12):1699-1704.
    55. Chavez A, McCraken A, A Berlinski. Effect of face bask static dead volume, respiratory rate, and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol. 2010; 45(3):224-229.
    56. A Berlinski, JR Willis, T Leisenring. In-vitro Comparison of 4 Large-volume Continuous Nebulizers. Respir Care. 2010; 55(12):1671-1679.
    57. R Willis, A Berlinski. Solution output of a large nebulizer during continuous nebulization: in-vitro vs. in-vivo study. Am J Respir Crit Care Med. 2009.
    58. Chavez A, McCraken A, Berlinski A. Effect of face mask static dead volume, respiratory rate and tidal volume on inhaled albuterol delivery. 2009; 179:A4833.
    59. R Willis, A Berlinski. Albuterol delivery by INTRAPULMONARY PERCUSSIVE VENTILATION (IPVĀ®) and a continuous jet nebulizer in a heated wire ventilator circuit utilizing a pediatric ventilator in-vitro model. 2009; 53(11):1545.
    60. B Downs, R Willis, A Berlinski. Accuracy of mixing albuterol solutions for inhalation. 2009; 53(11):1545.
    61. Willis L, Berlinski A. Aerosol delivery and airway clearence therapies in Cystic Fibrosis. 2009; Suppl 31:387-388.
    62. G Jones, A Berlinski. Concomitant use of continuous nebulized bronchodilators and heated high flow nasal canula in acute repsiratory distress in a child significantly decreases work of breathing. Respir Care. 2009.
    63. Berlinski A, Chavez A. Effect of mask dead space and inspiratory flow on albuterol delivery by metered-dose inhaler attached to a holding chamber. 2009; 22, 2:197.
    64. A Berlinski, R Willis. Effect of intermittent and continuous operation on nebulizer characteristic: an in-vitro study. Respir Care. 2009.
    65. Maffey AF, Berlinski A, Schkair JC, Teper AM. [Flexible bronchoscopy in a pediatric pulmonology service]. Arch Argent Pediatr. 2008 Feb; 106(1):19-25. PMID: 18636129.
      View in: PubMed
    66. Berlinski A, Carroll JL. Pediatric Respiratory Medicine. Eosinophilic lung diseases and hypersensitivity pneumonitis. 2008.
    67. Stroud MH, Okhuysen-Cawley R, Jaquiss R, Berlinski A, Fiser RT. Successful use of extracorporeal membrane oxygenation in severe necrotizing pneumonia caused by Staphylococcus aureus. Pediatr Crit Care Med. 2007 May; 8(3):282-7. PMID: 17417120.
      View in: PubMed
    68. R Willis, T Leisenring, Berlinski A. In-Vitro Comparison of 4 Continuous Nebulizers. 2007; 52 (11):1583.
    69. Shah SA, Berlinski AB, Rubin BK. Force-dependent static dead space of face masks used with holding chambers. Respir Care. 2006 Feb; 51(2):140-4. PMID: 16441958.
      View in: PubMed
    70. Berlinski A, Waldrep JC. Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med. 2006; 19(4):484-90. PMID: 17196077.
      View in: PubMed
    71. A Berlinski. The challenge of delivering aerosols to infants and children. Business Briefing U.S. Repiratory Care. 2006; 27-29.
    72. Berlinski A, M Ali, M Mazumder. Aerosol Characterization of nebulized dry powder formoterol. 2006; A82.
    73. S Shah, Berlinski A, B Rubin. Variability in holding chamber mask dead space volume and seal. Respir Care. 2006; 51(2):140-144.
    74. S Shah, Berlinski A, B Rubin. Variability in holding chamber mask dead space volume and seal. 2005; A236.
    75. CD Kofman, SM Zaragoza, Berlinski A, AF Maffey, SM Vidaurreta, AJ Colom, AM Teper. Comparison of the Bronchodilator Response to Albuterol Delivered by a Jet and an Ultrasonic Nebulizer in Asthmatic Children. 2004; A150.
    76. Berlinski A, F Navarra, M Ivancic, S Fernandez, S Lubovich, G Szulman, P Meyer, V Rodriguez, C Molise, A Maffey, A Teper. Risk Factors for Protracted Clinical course in Infants hospitalized with Bronchiolitis. 2004; A142.
    77. C Kofman, Berlinski A, S Zaragoza, A Teper. Aerosol therapy for pediatric outpatients. RT J Resp Care Pract. 2004; 17:26-28.
    78. Berlinski A, U Emre. Effect of delivery angle on aerosolized bronchodilator output of jet nebulizer. 2004; 817S.
    79. C Kofman, S Zaragoza, Berlinski A, J Muntadas, S Vidaurreta, A Teper. Aerosol therapy in outpatients from a tertiary care children's hospital. 2003; A388.
    80. Kofman C, Berlinski A. C Macri y A Teper Eds. Aerosolterapia in Enfermedades Respiratorias Pediatricas. 2003.
    81. Maffey A, Berlinski A. C Macri y A Teper Eds. Lavado Bronchoalveolar, in Enfermedades Respiratorias Pediatricas. 2003.
    82. Berlinski A, Fan LL, Kozinetz CA, Oermann CM. Invasive mechanical ventilation for acute respiratory failure in children with cystic fibrosis: outcome analysis and case-control study. Pediatr Pulmonol. 2002 Oct; 34(4):297-303. PMID: 12205571.
      View in: PubMed
    83. Berlinski A, Navarra F, Ivancic M, Fernandez S, Zaragoza S, Castineiras A, Teper A. Bronchiolitis: inpatient population admitted to a tertiary care children's hospital in Argentina. 2002; A675.
    84. Berlinski A, Waldrep JC. Nebulized drug admixtures: effect on aerosol characteristics and drug output of nebulized albuterol. 2001; A442.
    85. Maffey A, Berlinski A, Guagnini M, Fernandez S, Vidaurreta S, Teper A. Flexible fiberoptic bronchoscopy (FBB) in a pediatric pulmonary section: preliminary experience. 2001.
    86. Berlinski A, Waldrep JC. Is there a need for drug furmulation/delivery device indication? Nebulized beclomethasone: a bench study. 2000; A35.
    87. Oermann CM, Berlinski A, Fan LL, Kozinetz CA. Mechanical Ventilation Due to Acute Respiratory Failure in Cystic Fibrosis: Outcome Analysis and Case-control Study. 1999; 287.
    88. Sweet SC, Berlinski A, Mendeloff EN, Mallory Jr GB, Huddleston CB. Early graft dysfunction in pediatric lung transplant recipients. 1999; 82.
    89. Berlinski A, Waldrep JC. Bench testing of nebulized intranasal glucocorticoid formulations. 1999; A120.
    90. Berlinski A, Waldrep JC. Continuous albuterol nebulization: aerosol characterization. 1998; A639.
    91. Berlinski A, Waldrep JC. Metering performance of different metered-dose inhalers and spacers/holding chambers combinations. 1998.
    92. Berlinski A, Waldrep JC. Effect of aerosol delivery system and formulation on nebulized Budesonide output. 1997; A351.
    93. Berlinski A, JC Waldrep. Effect of aerosol delivery system and formulation on nebulized Budesonide output. J Aerosol Medicine. 1997; 10(4):307-318.
    94. Berlinski A, Teper AM. Metacholine inhalation test: comparison between three protocols varying metacholine dose (standard, weight and heigh adjustment) in pediatric asthmatic population. 1996; A558.
    95. Berlinski A. Effect of time and initial volume on final sodium concentration of nebulized isotonic saline solution. 1995; A745.
    Berlinski's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _